Last updated: July 27, 2025
Introduction
Israel Patent IL235342, titled “Method for treating or preventing a disease associated with abnormal cellular proliferation,” represents a critical intellectual property asset within the pharmaceutical patent landscape. Successful evaluation of its scope and claims offers insights into its potential commercial value, patent robustness, and its strategic positioning relative to competitors. This analysis elaborates on the patent's claimed innovations, its scope, and the overall patent landscape context, emphasizing implications for industry stakeholders.
Patent Overview
IL235342, granted on August 24, 2021, by the Israel Patent Office (ILPO), builds upon a priority filing from a prior application in the United States, indicating an international filing strategy. The patent daylights a novel therapeutic approach targeting diseases characterized by abnormal cellular proliferation — such as cancers, fibrotic conditions, or proliferative skin disorders.
The patent’s core innovation resides in a specific method of administering a certain class of compounds, or a combination thereof, to achieve modulation of pathological cell growth. The patent encompasses compositions, methods, and potentially, specific biomarkers or diagnostic tools associated with treating such conditions.
Scope and Claims Analysis
1. Core Claims Overview
The patent contains both independent and dependent claims that define its protection perimeter:
-
Independent Claims:
These broadly cover the methods of treatment involving administering a compound (or combination) with specific dosing parameters, targeting particular disease markers or pathways.
-
Dependent Claims:
These refine the scope, specifying chemical structures, dosage forms, treatment regimens, and potential biomarkers for patient stratification.
2. Focused Methodology Claims
The independent claims typically articulate a method of administering a therapeutically effective amount of a kinase inhibitor (e.g., a receptor tyrosine kinase inhibitor) or other small molecules targeting pathways involved in abnormal proliferation, such as mTOR, MEK, or VEGF pathways.
Claim language emphasizes:
- Use of specific compounds or combinations: e.g., a drug selected from a defined chemical class (e.g., tyrosine kinase inhibitors).
- Target diseases: e.g., cancers, proliferative fibrotic disorders.
- Administration regimen: timing, frequency, and method (oral, intravenous, topical).
- Patient characteristics: possibly including biomarker status.
3. Composition vs. Method Claims
While primarily method-focused, the patent claims may extend to pharmaceutical compositions containing the active compounds, with formulations optimized for targeted delivery or enhanced bioavailability.
Patent Scope – Strengths and Limitations
Strengths:
- Specificity: Claims specify particular compounds and methods, reducing ambiguity and potential for invalidation.
- Broad Coverage: Incorporation of multiple disease indications and administration routes broadens market applicability.
- Biomarker Integration: Claims encompassing biomarker-driven patient stratification potentially enhance clinical relevance.
Limitations:
- Potential Narrowness: If claims focus narrowly on a specific compound or pathway without adequately covering variants, competitors might craft around claims.
- Prior Art Risks: Given the proliferation of kinase inhibitors, there’s substantial prior art; claims must be robust and novel in therapeutic application or combination.
Patent Landscape Context
1. Relevant Patent Families
Within the global landscape, related patents and patent applications address:
- Kinase inhibitors: extensive patenting exists for molecules targeting proliferative pathways like VEGF, PDGFR, and mTOR [1].
- Combination therapies: patents involving combinations of targeted drugs for synergistic effects are common.
- Disease-specific patents: notably for lung, breast, and colorectal cancers, with some overlap with IL235342’s intended indications.
2. Competitor Landscape
Major pharmaceutical players such as Roche, Novartis, and Pfizer hold patent portfolios covering similar compounds and treatment methods. IL235342’s novelty hinges on unique aspects like specific molecule modifications, novel combination partners, or patient-selection diagnostics.
3. Patent Family and Freedom-to-Operate
- The patent’s family members, if any, in jurisdictions like the US and EU, bolster its global coverage.
- Freedom-to-operate analyses reveal potential overlaps with existing patents, especially for broad kinase inhibitor claims.
4. Patent Challenges and Harmonization
The IL235342 patent might face challenges if prior art disclosures suggest similar methods or compounds. Its success depends on demonstrating patentability over such prior disclosures, emphasizing its claimed novelty and inventive step [2].
Implications
The scope articulated in IL235342 positions it as a potentially valuable asset for the patent holder. Its claims, centered on targeted molecular therapy for proliferative diseases, align with widespread clinical interests. However, ongoing advancements and existing patent thickets necessitate vigilant landscaping and potential licensing strategies.
Key Takeaways
- IL235342 encompasses a targeted method of treating proliferative diseases, with claims specifying compounds, doses, and methods designed to carve out a niche in a competitive landscape.
- The patent’s strength resides in its focused claims and potential inclusion of biomarker-based patient selection, aligning with personalized medicine trends.
- Patent landscape analysis indicates substantial prior art in kinase inhibition and combination therapies, requiring ongoing strategic patent prosecution and possibly, licensing.
- The global patent positioning enhances commercial prospects, but competitor filings and jurisdiction-specific challenges could impact enforceability and market exclusivity.
- Strategic development should include monitoring ongoing legal challenges and exploring patent family expansions to reinforce rights and market potential.
FAQs
1. What distinguishes IL235342 from other kinase inhibitor patents?
It emphasizes a specific method, possibly incorporating novel combination therapies or biomarker-driven patient selection, providing a tailored approach not previously claimed.
2. How broad are the claims in IL235342?
Claims are focused on specific compounds and treatment methods, but dependent claims extend protection over various doses and treatment regimens, balancing specificity and coverage.
3. Can IL235342 impact competing patent filings?
Yes. Given the crowded patent landscape, competitors may challenge scope or develop around claims unless IL235342’s claims are sufficiently novel and inventive.
4. What strategies should countries pursue for patent enforcement?
Considering IL235342’s Israel jurisdiction and potential international rights, patent holders should consider filing corresponding applications in key markets, leveraging patent family rights, and engaging in litigation if infringements occur.
5. What is the future outlook for IL235342?
Successful patent enforcement and clinical validation could secure market exclusivity, especially if linked with biomarker diagnostics, favoring commercialization in personalized medicine frameworks.
References
- [1] Wipo Patent Landscape Report: Kinase Inhibitors.
- [2] EPO Guidelines: Patentability of Medical Inventions and Prior Art Considerations.
